Giarraputo Alessia, Barison Ilaria, Fedrigo Marny, Burrello Jacopo, Castellani Chiara, Tona Francesco, Bottio Tomaso, Gerosa Gino, Barile Lucio, Angelini Annalisa
Cardiovascular Pathology and Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
Laboratory for Cardiovascular Theranostics, Cardiocentro Ticino Foundation, 6900 Lugano, Switzerland.
Biomolecules. 2021 Feb 1;11(2):201. doi: 10.3390/biom11020201.
Cardiac allograft rejection following heart transplantation is challenging to diagnose. Tissue biopsies are the gold standard in monitoring the different types of rejection. The last decade has seen an increased emphasis on identifying non-invasive methods to improve rejection diagnosis and overcome tissue biopsy invasiveness. Liquid biopsy, as an efficient non-invasive diagnostic and prognostic oncological monitoring tool, seems to be applicable in heart transplant follow-ups. Moreover, molecular techniques applied on blood can be translated to tissue samples to provide novel perspectives on tissue and reveal new diagnostic and prognostic biomarkers. This review aims to provide a comprehensive overview of the state-of-the-art of the new methodologies in cardiac allograft rejection monitoring and investigate the future perspectives on invasive and non-invasive rejection biomarkers identification. We reviewed literature from the most used scientific databases, such as PubMed, Google Scholar, and Scopus. We extracted 192 papers and, after a selection and exclusion process, we included in the review 81 papers. The described limitations notwithstanding, this review show how molecular biology techniques and omics science could be deployed complementarily to the histopathological rejection diagnosis on tissue biopsies, thus representing an integrated approach for heart transplant patients monitoring.
心脏移植后的心脏同种异体移植排斥反应诊断具有挑战性。组织活检是监测不同类型排斥反应的金标准。在过去十年中,人们越来越强调识别非侵入性方法,以改善排斥反应的诊断并克服组织活检的侵入性。液体活检作为一种高效的非侵入性诊断和肿瘤预后监测工具,似乎适用于心脏移植随访。此外,应用于血液的分子技术可以转化到组织样本中,为组织提供新的视角并揭示新的诊断和预后生物标志物。本综述旨在全面概述心脏同种异体移植排斥反应监测新方法的最新进展,并探讨侵入性和非侵入性排斥反应生物标志物识别的未来前景。我们检索了最常用的科学数据库,如PubMed、谷歌学术和Scopus中的文献。我们提取了192篇论文,经过筛选和排除过程后,将81篇论文纳入本综述。尽管存在所述的局限性,但本综述展示了分子生物学技术和组学科学如何能够与组织活检的组织病理学排斥反应诊断互补应用,从而代表了一种用于心脏移植患者监测的综合方法。